Drug Profile
Anti-BCMA chimeric antigen receptor T cell therapy - Wuhan Bio Raid Biotechnology
Alternative Names: Anti-BCMA-CAR-T-Wuhan-Bio-Raid-Biotechnology; Anti-BCMA-chimeric-antigen-receptor-T-cell-therapy-Wuhan-BioLatest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Wuhan Bio-Raid Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological malignancies
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for clinical-Phase-Unknown development in Haematological-malignancies(Recurrent, Second-line therapy or greater) in China (Parenteral)
- 29 Aug 2016 Clinical trials in Haematological malignancies in China (Parenteral) (ChiCTR-OPC16009113)